1. López-Dupla M, Mora Sanz P, PintadoGarcía V, et al. Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases. Am J Gastroenterol. 1992;87(12):1771–6.
2. Takahashi Y, Nagata N, Shimbo T, et al. Long-term trends in esophageal candidiasis prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80,219 patients. PLoS One. 2015;10(7):e0133589. https://doi.org/10.1371/journal.pone.0133589. (Published 2015 Jul 24).
3. Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis. 1997;24(6):1204–7. https://doi.org/10.1086/513664.
4. Vazquez JA. Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl). 2010;2:89–101. https://doi.org/10.2147/hiv.s6660.
5. Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America [published correction appears in MMWR Morb Mortal Wkly Rep. 2005 Apr 1;54(12):311]. MMWR Recomm Rep. 2004;53(RR-15):1–112